ETX101

Phase 2Small molecule

EEncoded Therapeutics

ETX101 is one of 5 small molecule programs targeting Dravet syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dravet SyndromeActive, not recruiting

Dravet SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Dravet Syndrome

#DrugCompanyPhaseTrials

Fintepla

IImmedica Pharma AB

Approved

2 2

Fintepla

UCB

Approved

3 3

Zorevunersen

SStoke Therapeutics, Inc

Phase 3

2 4

ETX101

EEncoded Therapeutics

Phase 2

3 5

Diacomit

BBiocodex

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1/2Active, not recruiting

Dravet Syndrome

NCT06112275

Q4 2030

Phase 1/2Active, not recruiting

Dravet Syndrome

NCT06283212

Q1 2033

PreclinicalRecruiting

Dravet Syndrome

NCT05419492

Clinical

Trials by Indication[1]

Dravet syndrome3 trials

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Active, not recruiting·EEncoded Therapeutics·Phase 1/2·NCT06112275·4 enrolled

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

Active, not recruiting·EEncoded Therapeutics·Phase 1/2·NCT06283212·5 enrolled

ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome

Recruiting·EEncoded Therapeutics·Preclinical·NCT05419492·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ETX101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ETX101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ETX101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Encoded Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEncoded Therapeutics

ETX101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q4 2030

Q1 2033

Trials by Indication[1]

Dravet syndrome3 trials

References

Drug Info

Quick Facts

Related News